Subscribe to RSS
DOI: 10.1160/TH10-01-0025
BMS-593214, an active site-directed factor VIIa inhibitor: Enzyme kinetics, antithrombotic and antihaemostatic studies
Publication History
Received:
09 January 2010
Accepted after minor revision:
02 February 2010
Publication Date:
24 November 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/201002/lookinside/thumbnails/10-1160-th10-01-0025-1.jpg)
Summary
Factor (F) VIIa in association with tissue factor (TF) is the primary in vivo initiator of blood coagulation and activates FX and FIX to generate thrombin, which plays a key role in the pathogenesis of thrombosis. We evaluated the enzyme kinetics, antithrombotic and antihaemostatic properties of BMS-593214, an active-site, direct FVIIa inhibitor. Studies were conducted in enzymatic assays, and in anesthetised rabbit models of electrically-induced carotid arterial thrombosis (AT), thread-induced vena cava venous thrombosis (VT) and cuticle bleeding time (BT). Antithrombotic efficacy of BMS-593214 given intravenously was evaluated for both the prevention and treatment of AT and VT. BMS-593214 displayed direct, competitive inhibition of human FVIIa in the hydrolysis of a tripeptide substrate with Ki of 5 nM. However, it acted as a noncompetitive inhibitor of the activation of the physiological substrate FX by TF/VIIa with Ki of 9.3 nM. BMS-593214 showed selectivity for FVIIa and exhibited species differences in TF-FVIIa-dependent anticoagulation with similar potency in human and rabbit plasma. BMS-593214 was efficacious in the prevention and treatment models of AT and VT with ED50 values of 1.1 to 3.1 mg/kg. Furthermore, BMS-593214 exhibited a wide therapeutic window with respect to BT. These results suggest that inhibition of FVIIa with small-molecule active-site inhibitors represents a promising antithrombotic approach for the development of new therapies for the prevention and treatment of AT and VT.
-
References
- 1 Weitz I J. New oral antiocagulants in development. Thromb Haemost 2010; 103: 62-70.
- 2 Phillips KW, Ansell J. The clinical implications of new oral anticoagulants: will the potential advantages be achieved?. Thromb Haemost 2010; 103: 34-39.
- 3 Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 1687-1693.
- 4 Ott I. Tissue factor inhibition: another approach reducing thrombosis after vascular injury. Thromb Haemost 2010; 103: 7-8.
- 5 Lee AY, Vlasuk GP. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med 2003; 254: 313-321.
- 6 Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731.
- 7 Shirk RA, Vlasuk GP. Inhibitors of Factor VIIa/tissue factor. Arterioscler Thromb Vasc Biol 2007; 27: 1895-1900.
- 8 Harker LA, Hanson SR, Wilcox JN. et al. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26 (Suppl. 01) 76-82.
- 9 Kelley RF, Refino CJ, O'Connell MP. et al. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997; 89: 3219-3227.
- 10 Himber J, Kirchhofer D, Riederer M. et al. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997; 78: 1142-1149.
- 11 Jiao J, Kelly AB, Marzec UM. et al. Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site. Thromb Haemost 2010; 103: 224-233.
- 12 Suleymanov OD, Szalony JA, Salyers AK. et al. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther 2003; 306: 1115-1121.
- 13 Szalony JA, Suleymanov OD, Salyers AK. et al. Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time. Thromb Res 2003; 112: 167-174.
- 14 Olivero AG, Eigenbrot C, Goldsmith R. et al. A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. J Biol Chem 2005; 280: 9160-9169.
- 15 Young WB, Mordenti J, Torkelson S. et al. Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model. Bioorg Med Chem Lett 2006; 16: 2037-2041.
- 16 Groebke Zbinden K, Banner DW. et al. Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity. Bioorg Med Chem 2006; 14: 5357-5369.
- 17 Zhou J, Robinson L, Gubernator NM. et al. Tetrahydroquinoline derivatives as antithrombotic agents. 2004; US Patent number: US6825208 B2.
- 18 De Lucca I, Zhou J, Saiah E. et al. A selective FVIIa inhibitor with efficacy in an arterial thrombosis model. Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1. 2005
- 19 Wong PC, Crain EJ, Xin B. et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 06: 820-829.
- 20 Krishnaswamy S, Betz A. Exosites determine the macromolecular substrate recognition by prothrombinase. Biochemistry 1997; 36: 12080-12086.
- 21 Mousa SA, Wityak J. Orally active isoxazoline GPIIb/IIIa antagonists. Cardiovasc Drug Rev 1998; 16: 48-61.
- 22 Quan ML, Lam PY, Han Q. et al. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4– [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 2005; 48: 1729-1744.
- 23 Wong PC, Crain EJ, Watson CA. et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost 2009; 07: 1313-1320.
- 24 Baugh RJ, Dickinson CD, Ruf W. et al. Exosite interactions determine the affinity of factor X for the extrinsic Xase complex. J Biol Chem 2000; 275: 28826-28833.
- 25 Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost 2003; 89: 112-121.
- 26 Bajaj SP, Joist JH. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. Semin Thromb Hemost 1999; 25: 407-418.
- 27 Wong PC, Crain EJ, Watson CA. et al. Nonpeptide factor Xa inhibitors III: Effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther 2002; 303: 993-1000.
- 28 Himber J, Wohlgensinger C, Roux S. et al. A. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost 2003; 01: 889-895.
- 29 Morrissey JH. Tissue factor: in at the start… and the finish?. J Thromb Haemost 2003; 01: 878-880.
- 30 Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue factor-induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIA, XIa and thrombin. Thromb Haemost 2010; 104: 302-310.
- 31 Wong PC, Crain EJ, Watson CA. et al. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thromb Haemost 2009; 101: 108-115.
- 32 Mackman N. Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol 2005; 25: 2273-2281.